Takeda will keep OTC biz even after closing costly Shire deal

Jan 08, 2019

Takeda Pharmaceutical will likely hold onto its over-the-counter drug business even with pressure to improve its finances after closing its $59 billion takeover of Shire. Takeda will become one of the pharma world's most indebted after the deal and so will be aiming to sell up to $10 billion in assets.

"It’s not our first priority," said chief executive Christophe Weber when asked whether Takeda would sell its OTC business.

The global company has also secured $29.7 billion in bank loans.

Read the Reuters report

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments